Iluvien Registry Safety Study

NCT01998412 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 559

Last updated 2019-03-20

No results posted yet for this study

Summary

The study will include any patient treated with Iluvien at designated sites in European countries where marketing authorization has been granted in order to obtain broader safety and usage information.

Conditions

  • Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies

Sponsors & Collaborators

  • Alimera Sciences

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01998412 on ClinicalTrials.gov